tak-071
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02769065)
Timeline
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M1ACTIVATOR
CHRM1 activator
- Muscarinic acetylcholine receptor M1POSITIVE ALLOSTERIC MODULATOR
Muscarinic acetylcholine receptor M1 positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(Cc2ccc(-n3cccn3)cc2)cc2c(c1F)CN([C@H]1COCC[C@@H]1O)C2=O- Mol. weight
- 421.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594351 ↗
Also known as
- tak-071
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04334317 | Phase 2 | Jun 30, 2020 | Takeda |
| NCT02918266 | Phase 1 | Dec 5, 2016 | Takeda |
| NCT02769065 | Phase 1 | May 1, 2016 | Takeda |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 3 | 3 | 2 | 2016 |
1 organizations
Page 1 / 1